Scancell forms research pact with US antibody company

  • Mon 20 Jan 2020 07:38

    Immunotherapy developer for cancer Scancell said it had signed a collaboration and research agreement with a US-based, clinical-stage antibody company that it did not identify.

    The non-exclusive pact would see Scancell assess monoclonal antibodies targeting tumour-associated glycans, including those that had been enhanced with Scancell's proprietary AvidiMab technology.

    The new collaboration partner would conduct pre-clinical studies to evaluate Scancell's anti-TaG mAbs for the treatment of cancer.



<< Back <<

Scancell Holdings (SCLP)

6.30 0.00 (0.00%) delayed 16:57PM
Price delayed by 15 minutes.